LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
暂无分享,去创建一个
H. Iwata | D. Juric | S. Loibl | F. André | M. Campone | Kenichi Inoue | Masato Takahashi | P. Conte | B. Kaufman | Z. Pápai | H. Rugo | T. Yamashita | E. Ciruelos | D. Mills | G. Rubovszky | M. Kaper | I. Mayer | Y-S. Lu | F. Ghaznawi | M. Miller